Trial Profile
A Phase 2 Trial of Pembrolizumab Plus Bevacizumab in Patients With Metastatic Melanoma or Non-small Cell Lung Cancer With Untreated Brain Metastases
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Pembrolizumab (Primary)
- Indications Brain metastases; Malignant melanoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Feb 2024 Planned End Date changed from 1 Jan 2025 to 31 Jul 2025.
- 15 Feb 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Apr 2025.
- 01 Nov 2023 Planned End Date changed from 1 May 2024 to 1 Jan 2025.